- Category
- Micro (2021-22)
- Udyam number
- UDYAM-MH-19-0060851

Cardimes Pharmaceuticals Private Limited
About Cardimes Pharmaceuticals Private Limited
Data last updated:
Cardimes Pharmaceuticals Private Limited is a private limited company based in Mumbai, Maharashtra, India. It operates in the specialised services segment of the trading and commerce sector. It was incorporated on 01 February 2021 and has been in existence for over 5 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U51909MH2021PTC354266.
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹7.69 Lakh. It is led by directors including Md Mohsin Hashmi (Managing Director) and Hafsa Khatoon.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 307 Building Name Atl Corporate Park, Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.64 Cr, a growth of 33% compared to the previous year. For the same year it recorded a net loss of ₹11.97 Lakh (net margin -7.3%) and EBITDA of -₹9.35 Lakh (EBITDA margin -5.7%). Revenue has grown at a compounded annual rate (CAGR) of 42% over three years.
The company has about 16 employees on its provident fund (EPFO) records.
Cardimes Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0060851).
Company details
Recognitions & Rankings of Cardimes Pharmaceuticals
Contact details
Cardimes Pharmaceuticals Private Limited's registered office is in Mumbai, Maharashtra.
- Registered AddressOffice No. 307 Building Name Atl Corporate Park, Saki Vihar Road Opposite L And T Gate No.7 Powai, Mumbai, Maharashtra, India – 400072
- IndustryTrading, Specialty, Wholesale
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Cardimes Pharmaceuticals is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations |
To see the full business activity and turnover split of Cardimes Pharmaceuticals Private Limited, buy the company report.
Financials of Cardimes Pharmaceuticals Private Limited
FY 2025 filings availableCardimes Pharmaceuticals Private Limited reported revenue of ₹1.64 Cr (up 33% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 42% over three years, including 33% growth in the latest year. EBITDA rose 83% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹9.35 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹11.97 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -5.7% | ||||
| Net Profit Margin | -7.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Cardimes Pharmaceuticals Private Limited, buy the company report.
Board of directors of Cardimes Pharmaceuticals Private Limited
Cardimes Pharmaceuticals has 4 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Hafsa Khatoon | Director | 11 Jan 2022 | 4 Years 10 Months | Current |
| Mohammad Shakir Also directs: Safa Mount Private Limited | Director | 01 Feb 2021 | 5 Years 9 Months | Current |
| Md Mohsin Hashmi | Managing Director | 01 Feb 2021 | 5 Years 9 Months | Current |
| Ejaz Ahmad Rabbani | Director | 01 Feb 2021 | 5 Years 9 Months | Current |
Legal cases
No court or tribunal cases involving Cardimes Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Cardimes Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Cardimes Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Cardimes Pharmaceuticals Private Limited has 4 board changes on record since 2021: 4 appointments. The latest: Hafsa Khatoon was appointed as Director on 11 Jan 2022.
Frequently asked questions
Cardimes Pharmaceuticals is an active private limited company based in Mumbai, Maharashtra, India. The company works in specialty, within the trading industry. It was incorporated on 01 February 2021 (5+ years old) and is registered under CIN U51909MH2021PTC354266.
Cardimes Pharmaceuticals has 4 current directors:
- Md Mohsin Hashmi - Managing Director
- Hafsa Khatoon - Director
- Mohammad Shakir - Director
- Ejaz Ahmad Rabbani - Director
The latest financial statements of Cardimes Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2021 are in the company report.
The CIN (Corporate Identification Number) of Cardimes Pharmaceuticals is U51909MH2021PTC354266. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Cardimes Pharmaceuticals was incorporated on 01 February 2021, making it 5+ years old. It is registered with the Registrar of Companies, Mumbai.
Hafsa Khatoon was appointed as Director on 11 Jan 2022. Ejaz Ahmad Rabbani was appointed as Director on 01 Feb 2021. Md Mohsin Hashmi was appointed as Managing Director on 01 Feb 2021. Cardimes Pharmaceuticals has 4 board changes on record in total.
Yes, Cardimes Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-MH-19-0060851).
The registered office of Cardimes Pharmaceuticals is at Office No. 307 Building Name Atl Corporate Park, Saki Vihar Road Opposite L And T Gate No.7 Powai, Mumbai, Maharashtra, India – 400072.
Cardimes Pharmaceuticals operates in the trading industry, in the specialty segment.
Cardimes Pharmaceuticals can be reached at its registered office: Office No. 307 Building Name Atl Corporate Park, Saki Vihar Road Opposite L And T Gate No.7 Powai, Mumbai, Maharashtra, India – 400072.

